Background: Dolutegravir, an integrase strand-transfer inhibitor (STI), shows a high genetic barrier to resistance. Dolutegravir is reported to be effective against viruses resistant to raltegravir and elvitegravir. In this study, we report the case of a patient treated with dolutegravir monotherapy. Failure of dolutegravir treatment was observed concomitant with the appearance of N155H-K211R-E212T mutations in the integrase (IN) gene in addition to the polymorphic K156N mutation that was present at baseline in this patient.
Introduction
HIV-1 integrase (IN) catalyses viral DNA integration in the host cell genome. 1 To date, raltegravir, elvitegravir, and dolutegravir, known as integrase strand-transfer inhibitors (INSTIs), impair integration and have been approved to treat HIV-1-infected patients. These inhibitors are unable to bind IN alone but they bind to the pre-integration complex formed by IN and viral DNA and subsequently inhibit the strand-transfer reaction. 2, 3 Their modes of interaction have been well characterized: 4 (i) they chelate Mg 2! within the IN catalytic site; (ii) their halobenzyl group establishes p-stacking interactions with the long terminal repeat (LTR) base immediately upstream of the 3 0 -CA-OH; and (iii) they establish interactions with specific IN amino acids. Unfortunately, resistance mutations appear in raltegravir-experienced patients involving one of the three primary genetic pathways: Y143H/R/C, Q148H/R/K and N155H. [5] [6] [7] Cross-resistance between raltegravir and elvitegravir has been reported, highlighting the importance of developing new INSTIs. 8, 9 Dolutegravir is effective against viruses resistant to raltegravir, with changes involving the N155 and Y143 residues, but is less effective against Q148 viruses. [10] [11] [12] No pathway of dolutegravir resistance has been clearly identified. Some residues, however, have been shown to be involved in dolutegravir resistance, such as R263, G118 and F121. [12] [13] [14] [15] Interestingly, a combination of N155H and G140S/Q148H mutations has been reported to confer a high level of dolutegravir resistance whereas viruses with these residues individually are susceptible to dolutegravir. monotherapy. Cell-free studies showed that the N155H mutation conferred resistance to dolutegravir when the incubation time was increased. Also the addition of K211R/E212T and K156N mutations to N155H contributes to a gradual increase in resistance and particularly the contribution of K156N is remarkable allowing an increase of IC 50 by a 5-fold factor compared with N155H alone. A molecular modelling analysis completed the study demonstrating a decrease in the stability of dolutegravir on the preintegration complex when integrase carried an N155H mutation and even more when the other mutations described in the patient were added.
Patients and methods

Ethics
Information was obtained from the existing electronic database or medical records. Patients were informed that their demographic and clinical data would be recorded during their follow-up and their blood samples would be stored and could be used for retrospective studies and they gave their consent.
Cells and viruses
293-T and HeLa-P4 cells were cultured in DMEM and MT4 cells were cultured in RPMI-1640 and maintained at 37 C and 5% CO 2 . The media were supplemented with 10% heat-inactivated FBS. HIV-1 IN mutants were obtained by site-directed mutagenesis as previously described. 13 HIV-1 stocks were prepared by 293-T cell transfections and HIV-1 p24 gag antigen was quantified as previously described. 13 
HIV infectivity assay
Single-cycle titres of the virus were determined on HeLa-P4 cells as previously described. 13 Cells were infected in 96-well plates (3 ng of p24 gag antigen) with or without raltegravir or dolutegravir. Viral titre was determined by quantifying b-galactosidase activity in HeLa-P4 lysates using a colorimetric assay. The 50% effective concentration (EC 50 ) was defined as the drug concentration resulting in b-galactosidase levels that were 50% lower than those in infected cells without the drug.
Virus infections
Infections were performed on MT4 cells (2%10 6 cells/mL with 20 ng of p24 gag antigen per 10 6 cells) with or without drugs. Four hours postinfection, cells were washed in PBS and new medium was added. At various times post-infection, 1-2 million cells were harvested and dry pellets were frozen at -80 C.
DNA extraction and quantitative PCR
Total DNA from the previously described dry pellets was extracted using the QIAamp DNA Blood Mini Kit (QIAGEN). Quantifications of viral DNA forms (total viral DNA and integrated viral DNA) were performed by real-time PCR on a LightCycler instrument using the FastStart DNA Master HybProbe kit (Roche Diagnostics) as previously described. 16 Characterization of integrase enzymatic activity in cell-free reactions
Recombinant IN was purified under non-denaturing conditions, as previously described. 17 The susceptibility of IN to raltegravir and dolutegravir was determined in cell-free reactions by assessing IN activity in the presence of various concentrations of INSTIs using radiolabelled oligonucleotides U5B and U5B-2 mimicking the unprocessed and 3 0 -processed viral ends, respectively, as previously described. 13 IC 50 values were determined with Prism 5.0 software.
Docking and molecular dynamics simulations of dolutegravir against IN mutated complexes
Since it has proven difficult to crystallize the full-length HIV integrase and its complex with DNA and inhibitors, experimental structures derived from a related retrovirus, the prototype foamy virus (PFV), are available in the Protein Data Bank (PDB) (https://www.rcsb.org). Thus, for the computational analysis we used the crystal structures of WT and N224H (mimicking the N155H in HIV-1) mutated PFV intasome, in complex with Mg 2! and dolutegravir, deposited with PDB codes 3S3M and 3S3O, respectively. 18 We used the PFV IN model owing to the high level of conservation between INs. 19, 20 The mutations N224H, S225N, N280R and Q281T of the PFV IN sequence correspond to N155H, K156N, K211R and E212T in the HIV-1 IN sequence, respectively.
The mutated models were generated by single-residue replacement and the obtained structures were prepared using Maestro tools (software: Maestro, Schrödinger, LLC, New York, NY, 2017). For each complex, 10 000 MacroModel minimization steps were carried out using OPLS_2005 as a force field (software: MacroModel, Schrödinger, LLC, New York, NY, 2017). Docking studies were performed by means of the Induced Fit docking protocol using the Standard protocol and generating 20 poses for ligand. In the re-docking step the XP Glide algorithm was applied (software: Induced Fit docking protocol, Schrödinger, LLC, New York, NY, 2017). For each complex, the best docking pose, selected according to the GlideScore function, was submitted to Molecular Dynamics simulations (MDs). To analyse the dolutegravir thermodynamic profile, we calculated the DEmodel, expressed in kcal/mol, thus obtaining the difference in Emodel values between the WT sequence and the mutated complexes. The Emodel value has a more significant weighting of the force field components, which makes it well-suited to compare conformers and it is helpful to select the best-docked structure for each complex. Then, for each complex we submitted the best docking pose to 100 ns of MDs using the Desmond package v. 3.8 at a temperature of 300 K (software: Desmond Molecular Dynamics System, D.E. Shaw Research, New York, NY, 2017). The system was solvated in an orthorhombic box with a buffer of 10 Å , using TIP3P (transferable intermolecular potential with 3 points) water molecules as the solvent model, and counter ions were added to neutralize the system charge. To investigate the behaviour of dolutegravir during all trajectories, the ligand root mean square deviations (RMSD) with respect to the protein and its binding pocket were calculated. With a view to assess the occupancy and to appreciate the shift of dolutegravir from the IN binding site, we monitored the distance between the metal-chelating core of the drug and the 3 0 -deoxyadenosine of the viral DNA.
Results
Identification of N155H, K156N, K211R and E212T mutations in a patient failing dolutegravir treatment
The patient infected with a B subtype HIV-1 strain received an antiretroviral treatment including INSTIs from 2008 to 2015, a period during which CD4 counts had increased from 350 to 940 cells/mm 3 . The patient was first treated with raltegravir in combination with tenofovir/emtricitabine (Truvada) for 6 years until 2014, during which time the viral load remained undetectable (plasma HIV RNA ,20 copies/mL). Every 6 months, during follow-up, genotypic analysis of integrase was tested in DNA and never showed any mutations selected against raltegravir. Owing to treatment intolerance, a simplification of treatment with dolutegravir monotherapy (not currently recommended in any guidelines for HIV-1 treatment) was proposed to the patient in 2014 while the viral load was still undetectable.
The N155H pathway and dolutegravir resistance JAC Five months later, the viral load became detectable in plasma at 291 copies/mL. Integrase genotypic analysis was performed on DNA from PBMCs, when the plasma viral load was below 20 copies/ mL and on plasma RNA when it was detectable above 20 copies/ mL. Genotypic analysis before 2014 identified no resistance mutations, but a polymorphism was highlighted at position 156 with a K156N present throughout the study. Three weeks after the beginning of the dolutegravir monotherapy, a mixture of amino acid sequences appeared in the DNA at both positions 211 and 212, K211K/R (AAA/AGA codons) and E212E/A (GAA/GCA). Plasma RNA genotyping, 5 months after the start of dolutegravir monotherapy, confirmed the existence of the K211R (AGA) mutation at position 211, while at position 212 genotyping revealed an additional nucleotide mutation (GCA to ACA) leading to E212T instead of E212A. At the same time, N155H was also identified ( Table 1) .
Characterization of the mutations with cell-free and cell-based assays
We first investigated the replicative properties of mutant viruses. The p24 gag production of these mutants was similar to the WT showing that none of these mutations impaired the late steps of viral replication (Figure 1a , left panel and black columns). The early steps of HIV-1 replication were investigated by HeLa-P4 cell infection ( Figure 1a , left panel and grey columns). Interestingly, infectivity of the mutants was similar to the WT indicating that mutations identified in the patient do not impair the early steps of viral replication. The above-mentioned mutations could affect the 3 0 -processing and/or the strand-transfer reaction mediated by IN. Our cell-free reaction results demonstrate that the 3 0 -processing efficiency for all mutants was similar but significantly lower compared with the WT (an average of 50% of the WT, Figure 1a middle panel and black columns). However, the strand-transfer efficiency was not affected by any mutations (Figure 1a , middle panel and grey columns). Thus, all the mutations presented in this report slightly impair the 3 0 -processing but not the strand-transfer reaction. We performed resistance experiments using a 19-mer DNA (U5B-2) mimicking the 3 0 -processed DNA. The incubation for 2 h at 37 C, usually used, failed to reveal significant resistance to dolutegravir for any of the mutants (Figure 1a , right panel).
Then, we determined the EC 50 of each mutant by infecting HeLa-P4 cells in the presence of increasing concentrations of raltegravir and dolutegravir ( Figure 1b ). In the case of raltegravir, the K211R/E212T mutations do not confer resistance to raltegravir. This association of K211R/E212T mutations with N155H or N155H/ K156N mutations does not influence their resistance to raltegravir since the N155H, N155H/K156N, N155H/K211R/E212T and N155H/ K156N/K211R/E212T mutants display similar resistance to raltegravir (EC 50 between 24.5 and 54 nM). Regarding the dolutegravir experiment ( Figure 1b , left panel), our results do not highlight a significant resistance to dolutegravir for any of the viruses studied with EC 50 values equal to 1.4 and 1.5 nM for the WT and the K211R/E212T mutant respectively and between 1.2 and 1.6 nM for other mutants.
Mutations described in the patient confer dolutegravir resistance in cell-free reactions in a time-dependent manner Hightower and colleagues have shown that dissociation of dolutegravir from the IN-DNA complex was slower compared with raltegravir and elvitegravir whichever integrase mutations were tested. 21 We increased the incubation time of the strandtransfer reaction from 2 h to 48 h to evaluate its impact on the dolutegravir effect. Increasing the incubation time up to 48 h did not influence the IC 50 of dolutegravir for the WT (8 nM) highlighting the strong stability of the compound in the IN-DNA complex (Figure 2a and b) . Interestingly, we found a significant increase in the IC 50 as a function of time for all mutants (Figure 2b ). First, a significant IC 50 increase for the N155H mutant (from 8 nM for 2 h of incubation to 24 nM for 48 h of incubation) highlighted that the N155H mutation confers significant resistance to dolutegravir compared with the WT (Figure 2b ). Second, there was an increase in the IC 50 for the N155H/K211R/E212T mutant (from 16 nM for 2 h of incubation to 32 nM for 48 h of incubation) and a more important increase for the N155H/K156N/K211R/E212T mutant (from 20 nM for 2 h of incubation to 120 nM for 48 h of incubation). These results clearly show that mutations described in the patient, even the N155H mutation alone, provide resistance to dolutegravir when analysed in a longer timescale.
Mutations also confer dolutegravir resistance in a time-dependent manner in the virological context As previously shown, dolutegravir resistance could not be highlighted by classic b-galactosidase (CPRG) assays; thus, in order Malet et al.
to introduce the factor time, we used a pNL4.3 backbone encoding GFP under the control of 5 0 -LTR. 22 This viral construction allows a single round of infection and leads to high expression of GFP upon integration. Importantly, weak expression of GFP can be detected in unintegrated viral DNA. After infection of MT4 cells with both constructions (WT and N155H/K156N/ K211R/E212T) a similar percentage of GFP-positive cells was reached, indicating that these mutations do not influence reverse transcription. Furthermore, flow cytometry analyses demonstrated that integration was not impaired by N155H/ K156N/K211R/E212T mutations since the percentage of M2-positive cells at day 3 post-infection (cells expressing a high amount of GFP from integrated viral DNA) was quite similar (65% and 68% of the GFP-positive cells for N155H/K156N/ K211R/E212T and WT viruses, respectively) (Figure 3a) . Then, from day 3 to day 7 post-infection, the percentage of M2 cells decreased in the same way for both viruses (from 65% or 68% to 37%). This decrease is explained by silencing of the 5 0 -LTR containing the promoter responsible for GFP expression ( Figure  3a) . The same experiment was performed with dolutegravir (25 nM), added concomitantly with the viruses (Figure 3b) . As previously shown with CPRG assays (Figure 1d ), dolutegravir efficiently inhibits integration of both viruses as the percentage of M2 cells decreases from 68% to 4%, without or with dolutegravir, respectively (compare Figure 3a and b) . We observed a continuous decrease in the percentage of M2 cells for the WT virus (from 4% at day 3 to 1.5% at day 7); however, the N155H/ K156N/K211R/E212T virus showed an increase in M2 cells reaching a maximum at day 5, this increase being a consequence of greater integration since integrated DNA is the only template for such expression. 22 These data demonstrate that even if dolutegravir efficiently inhibits the WT virus as well as the 
Impact of mutations on the viral DNA forms during replication
Further experiments were performed on MT4 cells with WT and mutant viruses N155H, N155H/K156N and N155H/K156N/K211R/ E212T with or without dolutegravir (25 nM). Dolutegravir was added at the time of infection and then cells were regularly diluted in fresh medium. Total and integrated viral DNA were quantified as previously reported (Figure 4) . 23 For IN mutants we observed, with dolutegravir, an increase in total viral DNA as well as integrated viral DNA whereas they both declined for the WT infection, integrated viral DNA becoming undetectable after four days postinfection showing the ability of dolutegravir to inhibit the spread of the WT virus (Figure 4a and b) . For mutants, increased integrated DNA is directly correlated with the number of mutations ( Figure  4b ). Our results demonstrate that, in these settings, dolutegravir can efficiently inhibit the WT virus but, more importantly, dolutegravir does not inhibit the replication of the viruses harbouring mutations in a long-term manner.
Computational analysis of dolutegravir theoretical binding affinity and stability against IN mutated complexes
Although there are relevant differences in terms of corresponding amino acid positions (Table 2) , the PFV model used shows a high level of functional and structural similarities to HIV-1 IN. For all the mutated complexes, our structural analysis revealed that the dolutegravir energetic profile was unfavourable compared with that of the WT ( Figure 5 ). We noticed that in the presence of the N224H mutation (mimicking HIV-1 N155H), N224H-S225N mutations (mimicking HIV-1 N155H and K156N) and N224H-S225N-N280R-Q281T mutations (mimicking HIV-1 N155H-K156N- K211R-E212T), dolutegravir showed a lower theoretical binding affinity against IN with respect to that of the WT sequence (Table 2 ). In the WT complex, dolutegravir was involved in two stacking interactions, the first one between its 2, 4-difluorobenzyl ring and cytosine C16 from the C/G base pair of viral DNA and the second one between the metal-chelating core of the drug and the viral 3 0 -deoxyadenosine. In all mutated complexes, the dolutegravir 2, 4-difluorobenzyl ring was the only moiety able to maintain the stacking interaction with viral DNA cytosine C16 (Figure 6 ).
The RMSD of dolutegravir was calculated in the last 50 ns of MDs, after system equilibration, for the evaluation of the drug's stability. As shown in Figure 7a and Table 2 , in the WT complex the The Emodel value of DTG best pose in the presence of WT sequence and N224H, N224H-S225N, N224H-S225N-N280R-Q281T. The N155H pathway and dolutegravir resistance JAC drug remained stable during all the simulation. By contrast, for the N224H mutated complex, we noticed that dolutegravir slightly decreased its stability with respect to the WT trend. In the presence of the double N224H-S225N and the quadruple N224H-S225N-N280R-Q281T mutants, we observed reduced stability of dolutegravir with respect to both the WT and the single mutated complex.
During the whole trajectory, we monitored the distance between the metal-chelating core of dolutegravir and the 3 0 -deoxyadenosine of viral DNA (Figure 7b ). We observed that in the presence of mutations dolutegravir lost the stacking interaction with the 3 0 -deoxyadenosine of the viral DNA, if compared with the WT. Indeed, we showed that the average distance between dolutegravir and the 3 0 -deoxyadenosine of DNA during the whole MDs increased for N224H, N224H-S225N and N224H-S225N-N280R-Q281T structures with respect to that of the WT (Table 2) . We noticed that the distance between the dolutegravir metalchelating core and the 3 0 -deoxyadenosine of the viral DNA for the quadruple mutant complex was smaller with respect to that of the double mutant; this is probably due to a more favourable electrostatic interaction between the arginine280 and the phosphate groups of the viral DNA, thus justifying an increased stability trend for the N224H-S225N-N280R-Q281T mutated complex (Figure 7b ).
Discussion
Currently, specific dolutegravir resistance pathways have not yet been clearly identified, but the VIKING trials show that dolutegravir is efficient against most of the viral strains resistant to raltegravir and elvitegravir, particularly regarding the N155H mutation, but confers slight resistance when the Q148 residue is associated with secondary mutations. [24] [25] [26] Recently, we reported that a combination of mutations belonging to pathways Q148 and N155, each leading to raltegravir resistance, made it possible to develop high levels of resistance to dolutegravir. 12 In this report, four mutations have been studied regarding their participation in dolutegravir resistance. Firstly, the classical approach using HeLa-P4 cells showed that HIV-1 isolates involving mutations at the N155, K156, K211 and E212 amino acids do not show any resistance to dolutegravir whereas mutants involving the N155H mutation conventionally showed resistance to raltegravir (Figure 1b ). Cell-free reaction studies of the strand-transfer step showed that an increase in incubation time led to dolutegravir resistance, whereas the classical incubation time of 2 h did not distinguish mutants from the WT. Also, in a virological context, we demonstrated that inhibition by dolutegravir was only transient for the N155H-K156N-K211R-E212T mutant unlike the WT virus. These results could be consistent with observations made by Hightower and colleagues showing that dolutegravir harboured slower dissociation rates on mutated IN-DNA complexes harbouring the N155H mutation compared with raltegravir. 21 All these data show that N155H mutation confers some resistance to dolutegravir that is increased in a consistent way when K211R/ E212T and K156N mutations are added. From a clinical point of view, two patients receiving dolutegravir have already been reported with an emerging N155H mutation reinforcing the idea that selection of this mutation could be responsible for resistance to dolutegravir. 27 Regarding the K156N polymorphic mutation detected at a frequency of about 10%, 28 it could play a key role in the selection of N155H mainly owing to its impact on IC 50 measurement when associated with N155H. For this reason, it would be interesting to know the genetic profile of integrase in the two patients described above. In addition, a report suggests the importance of K156N as a secondary mutation of resistance to raltegravir 28 ; also, residue K156 is described as involved in the interactions between IN and the viral DNA ends. 29 As a result, K156N could play an important role in the selection of a virus resistant to dolutegravir.
We explained the apparent discrepancy between classical CPRG assays and cell-free experiments involving an increase in reaction time by the stability of dolutegravir on IN-DNA complexes and the time needed to properly reveal the results of the experiment. These hypotheses are reinforced by in silico studies that show that when mutations are present in IN, dolutegravir is less stable on the pre-integration complex depending on the number of mutations, probably due to the loss of one pivotal stacking interaction with the viral 3 0 -deoxyadenosine (A17) and the associated drug shift from the catalytic binding site, as highlighted by MDs, especially in the double N155H-K156N and the quadruple N155H-K156N-K211R-E212T mutants. These observations are completely in agreement with the role of 3 0 -deoxyadenosine in the stabilization and in the control of the kinetics of binding and dissociation of the INSTIs. 19, 30 According to the experimental data, our computational protocol could explain the resistance and the inability of the drug to block the enzyme activity in the presence of the analysed mutations, as shown by the disadvantaged energetic profile of dolutegravir and the loss of pivotal stacking interaction between the metal-chelating core of the drug and the adenine (A17) of the viral DNA, in the presence of the mutated complexes.
The results discussed here reveal that the stability of dolutegravir on the pre-integration complexes appears to be an important parameter that obviously contributes to its efficiency and could explain data obtained from the clinic in some patients failing dolutegravir treatment. Together, our results strongly suggest that the polymorphic mutation K156N could play a role in the selection of the N155H mutation leading to dolutegravir resistance. In this sense, it would be important to carefully explore the presence of this mutation in patients in whom dolutegravir therapy is failing in order to evaluate its involvement in dolutegravir resistance. The N155H pathway and dolutegravir resistance JAC
